South Korea's OliPass Corp. may not be a mainstream antisense drug company, but it has strong ambitions and the confidence to become a top global oligonucleotide therapeutics company with its platform technology, which it believes to be superior to that developed by some other companies like Ionis Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc.
"Many companies know about us, but say our data is too fantastic to believe," OliPass CEO Shin Chung said in...